Nautilus Biotechnology Raises $76 Million in Series B Funding to Be the First to Quantify the Human Proteome
May 21, 2020•about 5 years ago
Amount Raised
$76 Million
Round Type
series b
Description
Nautilus Biotechnology, a company pioneering a high-throughput, low-cost platform for analyzing and quantifying the human proteome, today announced it has raised $76 million in an oversubscribed Series B offering that closed on Monday, May 18, 2020. Nautilus’ total funding now exceeds $100 million. The Nautilus platform will deliver single-molecule sensitivity more quickly, more completely, and less expensively than is possible with existing technologies. This deeper, richer understanding of proteins will enable a dramatic acceleration of basic science research, significantly improve the success rate of therapeutic development, and speed the adoption of personalized and predictive medicine.
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech